All News

Breast cancer and melanoma survivor says you are allowed to feel what you are feeling, whatever that is.

Keytruda (pembrolizumab) was approved for the treatment of refractory or relapsed Hodgkin lymphoma.

Immunotherapy has drastically shaped the treatment of lung cancer. Vassiliki A. Papadimitrakopoulou, M.D., looks forward to what's next.

New guidelines may result in a small percentage of patients with breast cancer being misclassified and not receiving proper treatment, Michael F. Press, M.D., Ph.D., says.

My chemo’d brain and five ways that help me remember not to forget.

Only in a family like mine, where breast cancer comes up fairly often, would my daughter Kirtley call me into the bathroom to see a pimple on her breast at age 14.

Kisqali (ribociclib), a CDK 4/6 inhibitor, gained approval from the Food and Drug Administration (FDA) for the frontline treatment of postmenopausal women with hormone-receptor (HR)–positive, HER2-negative advanced breast cancer.

Multiple trials are testing the potential of immunotherapy combinations in breast cancer. The results are exciting, explains Elizabeth A. Mittendorf, M.D., Ph.D.

I guess I’m old school when it comes to a cancer diagnosis. I have always assumed there are three types of cancer—the good (which is a diagnosis of “no cancer”), the bad and the ugly.

Teaching the patient and caregiver reportable signs and symptoms and when to call the doctor cannot only save their line, but, more importantly, can save their life.” — WENDY A. NUNEZ , R.N.

Leo I. Gordon, M.D., discusses an exciting new trial for patients with non-Hodgkin lymphoma.

Reflections of sharing our story over this past year

Should patients avoid immunotherapy because of the side effects that have been reported? Dr. Lichtenfeld shares his thoughts.

The supplemental biologics license application (sBLA) for Keytruda (pembrolizumab) is still under review by the Food and Drug Administration (FDA) to treat MSI-H cancer.

Since 2000, and the hundreds of new approaches to cancer treatment, a new kind of patient has emerged — one who may live years beyond their initial prognosis by moving from treatment to treatment.

Marcia Goglia was given a laxative in the ER for what turned out to be ovarian cancer.

Charles Drake, M.D., Ph.D.. is optimistic about immunotherapy as it continues to move toward the frontline setting in GU cancers.

A recent phase 3 study showed that Imbruvica plus ublituximab may be a promising option for some patients with CLL.

Stereotactic body radiation therapy (SBRT) is highly effective, and potentially curable for early-stage lung cancer, though not many physicians use the therapy, says expert Molly Freeman, C.N.P.

Winning (and losing) the Academy Awards can be like fighting cancer.

Sometimes a cat isn't your problem, it's actually lymphoma.

A new documentary may change the conversation around cancer.

Cynthia Heath got the shock of her life when she learned she had colon cancer and a limited time to live. Now, she is an advocate for others who find themselves in the shoes she was in a decade ago.

Robert Andtbacka, M.D., C.M., discusses the importance of communication between patients and health care professionals during melanoma surgery.

Breast cancer and melanoma survivor ponders the heart of the cancer diagnosis--a lifetime of ongoing uncertainty.

Communication is often a big issue in cancer care.

Did you know that melanoma isn’t just skin cancer? It can also develop in the eyes (ocular melanoma) and in the mucous membranes of the body (mucosal melanoma).

My hair tells the world that treatment is over and I am a survivor. If only it were that simple.